Digitalis Ventures

Digitalis Ventures is a venture capital firm dedicated to addressing complex challenges in human and animal health. Founded in 2016 and headquartered in New York City, the firm invests in early-stage companies across the healthcare ecosystem, including biotechnology, health technologies, diagnostics, and animal health. Digitalis Ventures partners with entrepreneurs, scientists, and inventors at all stages of company development, providing support through multiple rounds of financing. The firm's multidisciplinary team combines technical, financial, and domain expertise to creatively finance, build, and scale enduring enterprises. Digitalis Ventures is part of the Digitalis Group, which also includes Digitalis Research and Digitalis Commons.

The firm's investment strategy focuses on identifying and supporting companies that leverage breakthrough science and technology to improve health outcomes. Digitalis Ventures has invested in over 50 companies across the United States, United Kingdom, and Europe, with notable investments such as Good Therapeutics, GRO Biosciences, Terray Therapeutics, Cayaba Care, and findhelp. In October 2022, Digitalis Ventures closed its fourth fund, totaling $300 million, to support entrepreneurs and researchers developing transformative solutions in health.

Digitalis Ventures' name is inspired by the Digitalis plant, known for its cardioactive properties, reflecting a commitment to scientific innovation and human connection. The firm is headquartered in New York City, with additional offices in Boston, Los Angeles, San Francisco, Gainesville, and Zurich. Digitalis Ventures is an equal opportunity employer, offering a collaborative and inclusive work environment for its team members.